Phase 1 Study Comparing How LY4065967 Tablet and Capsules Are Absorbed in Healthy Adults

What this Trial Is About

Researchers are evaluating three different forms of LY4065967a tablet and two types of capsulesin healthy adult participants to understand how much and how quickly each form enters the bloodstream after being swallowed. This Phase 1, randomized, open-label, crossover study aims to compare the relative bioavailability of these formulations while monitoring for any side effects. The study is sponsored by Eli Lilly and Company and focuses on basic science to improve knowledge of LY4065967 pharmacokinetics. Participants will receive LY4065967 orally in three separate treatment periods, each involving one of the three formulations a tablet, a capsule, or a formulated capsule. The treatment periods are organized in a crossover design, meaning each participant will receive all three forms in sequence. Each treatment period includes a stay of 3 nights in a Clinical Research Unit. Across the study, participants will have three such stays totaling about 7 weeks of involvement. During the study, participants will undergo medical evaluations including blood sampling to measure drug concentrations over time, electrocardiograms, and laboratory tests to assess health status and monitor safety. Researchers will measure pharmacokinetic outcomes such as maximum drug concentration and the area under the concentration-time curve. Throughout the study, side effects and drug absorption rates will be monitored. The total participation time lasts approximately 7 weeks, including three inpatient stays for detailed observation and testing.

A Study of LY4065967 in Healthy Participants